News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

inGenium Research, Inc. Names Jamie Oliver, Pharm.D., COO, Head Of Development


10/19/2005 5:11:37 PM

CARY, N.C., June 3 /PRNewswire/ -- Jamie Oliver, Pharm.D., a 20-year veteran of pre-clinical and clinical experimentation in academia and in the pharmaceutical industry, has been named chief operations officer and head of development for inGenium Research, Inc., a privately held Contract Research Organization headquartered in Cary, North Carolina.

Dr. Oliver has served over the past seven years as vice president of clinical development for public and private biotechnology companies, initiating and building clinical programs. He has overseen regulatory, pre- clinical research and development, and manufacturing operations of internal and external groups. Dr. Oliver has filed numerous INDs with the FDA and has direct experience with both CDER and CBER, while serving as the medical monitor and responsible party for the INDs.

"Dr. Oliver is well-known and highly respected in our industry, and we are fortunate to have him," said Dr. Joshua S. Baker, Ph.D., president and CEO of inGenium Research. "Our success springs directly from the range and the depth of experience of our people, and Dr. Oliver represents the very best we offer clients."

Dr. Oliver served as the associate director of medical affairs with ClinTrials Research (now Inveresk), where he was responsible for global pharmacovigilance as well as serving as the medical monitor for numerous national and international clinical studies. During his tenure at ClinTrials, Dr. Oliver assisted in compiling US and EMEA licensing applications for several drugs.

Prior to ClinTrials, Dr. Oliver directed the research operations of a large non-profit hemodialysis corporation, publishing numerous clinical and pre-clinical studies in collaboration with Emory University, Mercer University, and the Centers for Disease Control and Prevention in the areas of oncology, HIV, shock, cytokines, infectious diseases, immunopharmacology, renal disease, and transplantation.

inGenium Research ( http://www.ingen-inc.com/ ) is a privately held CRO located in Cary, North Carolina, focused on providing clinical research and strategic development services to pharmaceutical and biotechnology companies. inGenium provides assistance to companies in the areas of strategic planning, technology transfer, licensing, regulatory planning and submissions, pre- clinical development, and manufacturing, as well as providing fully integrated clinical trials support of clinical operations, data management and biostatistics, and regulatory dossier compilations.

For information contact: Josh Baker, President and CEO Dan Headrick inGenium Research, Inc. Public Relations 919.462.8867 919.332.9303 jsbaker@ingen-inc.comheadrickdan@hotmail.com

inGenium Research, Inc.

CONTACT: Josh Baker, President and CEO of inGenium Research, Inc.,+1-919-462-8867, or jsbaker@ingen-inc.com ; or Dan Headrick, Public Relationsfor inGenium Research, Inc., +1-919-332-9303, or headrickdan@hotmail.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES